OCUGEN, INC. (OCGN) Spending and interest coverage
- R&D / revenue · 12 months: Value 955.32%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 955.32% | Research and development expense / revenue. Period ending 2026-06-30. $43.76M ÷ $4.58M × 100 ≈ 955.32% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 43.76M USD | Research and Development Expense |
| Revenue | 4.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -68.90M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.76M | $4.58M | (m) | $-68.90M | (m) | 955.32% | (m) | (m) | (m) |
| 2026-03-31 | $41.48M | $4.46M | (m) | $-66.25M | (m) | 928.91% | (m) | (m) | (m) |
| 2025-12-31 | $39.75M | $4.41M | (m) | $-62.92M | (m) | 900.75% | (m) | (m) | (m) |
| 2025-09-30 | $37.37M | $5.37M | (m) | $-59.76M | (m) | 695.92% | (m) | (m) | (m) |
| 2025-06-30 | $34.33M | $4.75M | (m) | $-55.39M | (m) | 722.13% | (m) | (m) | (m) |
| 2025-03-31 | $34.83M | $4.52M | (m) | $-57.04M | (m) | 770.21% | (m) | (m) | (m) |
| 2024-12-31 | $32.13M | $4.05M | (m) | $-54.76M | (m) | 792.26% | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.70M | (m) | $-52.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $7.26M | (m) | $-51.62M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $6.61M | (m) | $-59.71M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $6.04M | (m) | $-65.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | $-81.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-88.75M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-84.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-84.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | $-75.29M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | $-62.96M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | $-69.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $0.00 | (m) | $-58.03M | $79.00K | (m) | (m) | -734.53× | Reported |
| 2021-09-30 | (m) | $-380.00 | (m) | $-47.26M | $224.96K | (m) | (m) | -210.10× | Reported |
| 2021-06-30 | (m) | $-380.00 | (m) | $-46.66M | $497.96K | (m) | (m) | -93.70× | Reported |
| 2021-03-31 | (m) | (m) | (m) | $-24.41M | $725.96K | (m) | (m) | -33.63× | Reported |
| 2020-12-31 | (m) | $42.62K | (m) | $-21.28M | $720.96K | (m) | (m) | -29.52× | Reported |
| 2020-09-30 | (m) | (m) | (m) | $-21.76M | $569.47K | (m) | (m) | -38.21× | Reported |
| 2020-06-30 | (m) | (m) | (m) | $-14.29M | $1.07M | (m) | (m) | -13.31× | Reported |
| 2020-03-31 | $5.94M | (m) | (m) | $-13.25M | $1.09M | (m) | (m) | -12.19× | Reported |
| 2019-12-31 | $8.09M | (m) | (m) | $-14.16M | $1.77M | (m) | (m) | -8.01× | Reported |
| 2019-09-30 | $14.57M | (m) | (m) | $-29.54M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.92M | (m) | $959.00K | $-27.84M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $13.93M | $0.00 | $1.33M | $-32.07M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $15.63M | $0.00 | $1.63M | $-30.11M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $15.67M | $0.00 | $1.59M | $-26.40M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $14.60M | $0.00 | $1.52M | $-25.12M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $14.35M | $0.00 | $1.48M | $-24.21M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $15.57M | $0.00 | $1.57M | $-24.95M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $17.52M | $0.00 | $1.70M | $-26.82M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $18.91M | $0.00 | $1.76M | $-27.76M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $20.50M | $0.00 | $1.73M | $-29.34M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $21.58M | $0.00 | $1.55M | $-30.31M | $60.00K | (m) | (m) | -505.12× | Reported |
| 2016-09-30 | $22.03M | $0.00 | $1.45M | $-30.71M | $77.00K | (m) | (m) | -398.90× | Reported |
| 2016-06-30 | $23.00M | $0.00 | $1.38M | $-32.11M | $81.00K | (m) | (m) | -396.37× | Reported |
| 2016-03-31 | $23.07M | $0.00 | $1.30M | $-31.74M | $90.00K | (m) | (m) | -352.71× | Reported |
| 2015-12-31 | $23.24M | $0.00 | $1.23M | $-31.82M | $133.00K | (m) | (m) | -239.24× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $26.04M | $0.00 | $547.00K | $-32.66M | $151.00K | (m) | (m) | -216.30× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |